INVESTING Together Changing LIVES

Total Page:16

File Type:pdf, Size:1020Kb

INVESTING Together Changing LIVES INVESTING TOGETHER CHANGING LIVES Keeping the UK at the heart of medical research CONTENTS WORKING TOGETHER FOR UK RESEARCH WORKING TOGETHER FOR UK RESEARCH 3 Over the past few decades, we have seen staggering improvements in the way that we prevent, diagnose and treat some of the most debilitating medical conditions. Medical RESEARCH IN THE UK 4 research carried out by talented scientists in our universities and research institutes and supported by funders across the public and private sector has transformed millions Government support 4 of lives across the world. The range of treatments and technologies available today is Other funding sources 5 unrecognisable from those on offer fifty years ago. The British Heart Foundation is Long-term Government investment will allow THE FUNDING ECOSYSTEM 9 the largest independent funder researchers to continue their world-leading of cardiovascular research, and research, maintaining the UK’s global position Direct vs indirect funding 9 the third largest charitable in life sciences, stimulating the economy and funder of medical research, in providing continuing improvements in the health Partnerships 9 the UK. Each year, thanks to the of the public, in Britain and globally. Cuts in the Multi-funder collaborations 10 vision and generosity of our Government’s funding of research, even if only supporters, we are able to fund applied in the short-term, would have profoundly Translational research 11 around £100 million of new research across the UK, damaging long term effects. They would supporting people, from PhDs to professors, as well discourage investment from other sources, such Research careers 11 as investing in large programme and project grants. as industry; reduce the amount of research which charities can fund; and damage the UK’s ability to We have been at the centre of the last fifty years retain and attract talent. of progress in cardiovascular research and we THE HEALTH Benefits OF INVESTMENT IN RESEARCH 14 are proud of the impact our work has delivered. We have come a long way in the fight against heart However, these achievements are not ours alone and disease but we still have much further to go. If we could not have done it without the input of the the British Heart Foundation is to continue its life THE ECONOMIC Benefits OF INVESTMENT IN RESEARCH 18 Government, other charitable funders and industry. saving work, the Government must work with us and continue to invest in research. As this report illustrates, rapid and transformational scientific progress is only achieved by a system of investors complementing each other’s work. UK Government is a central part of this funding system and its continued investment in science is essential if we are to build on the progress Simon Gillespie that we have made so far. BHF Chief Executive This report was written by Chloe Watson at the British Heart Foundation. 2 Investing together, changing lives – keeping the UK at the heart of medical research Investing together, changing lives – keeping the UK at the heart of medical research 3 ReseaRCH IN THE UK Government, industry and charitable funders each have their own role within the In 2010, despite significant financial pressures on government departments, the UK Government OTHER FUNDING SOURCES funding landscape for science and research. If one steps away, the others will be committed to protect the resource allocation unable to compensate. for science and research in cash terms. More Charities and the private sector are another vital recently, the Government also made a real-terms component of the UK funding ecosystem. Scientific research is one of the UK’s biggest This success has not been achieved overnight. commitment to investment in capital infrastructure Medical charities invest £1.3 billion annually in assets. It has led to some of the most important It is the result of stable, long-term commitment to 2021. These commitments have provided research, constituting a third of all publicly funded from researchers and investors alike to push the much-needed stability to the research community, advances in health and technology, from medical research7. the development of the first vaccine to the boundaries of research, and transform exciting allowing the sector to focus on generating world- invention of the World Wide Web. In the past 50 scientific discoveries into impact for patients. class research that adds to the knowledge base, The private sector also plays a crucial role in developing delivers health benefits to patients and contributes years, cardiovascular research has completely Long-term commitment from investors, including promising new treatments and technologies that have to the UK economy. transformed the lives of those living with heart the UK Government, continues to be vital in order emerged as a result of publicly funded research, as to support the sector, attract outside investment disease. We now see more people survive heart However, holding the science budget constant in it has the financial power to support later stages of and innovation to the UK, and ensure that research attacks than ever before, better diagnosis and cash terms means that its value is gradually eroded development, investing an estimated £4.1 billion in today results in benefits in the future. health research in 20138. treatment of inherited conditions, and more as a result of inflation. According to analysis from babies born with heart defects growing up to GOVERNMENT SUPPORT the Campaign for Science and Engineering, the The strength of the UK research base enables live healthy, productive lives. resource budget accumulated a real-terms shortfall researchers to attract substantial funding from 6 The core of the UK Government budget for science of £1 billion over the course of the last Parliament . international sources. The UK has won 16 per cent We have made remarkable progress but there and research is provided by the Department for It is too early to tell what impact this shortfall will of research funding from the European Framework is still much more to achieve. Cardiovascular Business, Innovation and Skills (BIS). BIS provides have on the sector. Programme (FP7) with only 12.7 per cent of the EU-28 funding for research through a ‘dual-support’ 9 disease (CVD) causes more than a quarter of We believe that continued long-term population . all deaths in the UK; the cost to the UK of system, whereby funds are allocated through annual block funding to higher education commitment from Government, maintained premature death, lost productivity, hospital institutions (HEIs) from Funding Councils5 and in line with inflation, is essential if the UK is treatment and prescriptions relating to CVD research grants from the seven UK Research to build on its position as a world-leader in is estimated at £15–19 billion each year; and Councils. The ‘dual-support’ system allows HEIs scientific research. healthcare costs alone total an estimated to maintain a solid research base whilst allowing £8–10 billion1. individual researchers the flexibility to pursue the most promising avenues of their research. The UK has a strong track record for generating Funding through both the Research Councils and high-quality research. When compared the Funding Councils is awarded on the basis of UK CHARITABLE internationally, it ranks second in the world for INDUSTRY GOVERNMENT InternationaL FUNDERS excellence, ensuring that research is conducted by the quality of its scientific research institutions2. the best possible people, wherever they may be. While the UK represents less than 1% of the world’s population, it produces 16% of top quality The science budget within BIS also includes support published research findings3. The strength of our for the National Academies, which promote science base enables us to attract and retain the excellence in UK science, engineering and the very best researchers to the UK and leverage further humanities and social science. The Department investment for world-class research. of Health provides support for research being WORLD class conducted within the NHS, through the National IT IS estiMateD THat THE lag BETWEEN Institute for Health Research. investMENT IN caRDIOvasculaR A prosperous research environment depends on ReseaRCH ReseaRCH AND its eventual IMPact long-term investment, with a balance between ON Patients IS AROUND 17 YEARS4, MAKING investment in science capital and resource. Whilst new, state-of-the-art facilities and equipment, LONG-TERM INVESTMENT ESSENTIAL. 1 BHF & CEBR analysis 2014 requiring capital spend, provide an exciting 2 World Economic Forum, Global Competitiveness Report, 2014-2015 opportunity for UK research, they will be unable 3 Elsevier, International Comparative Performance of the UK Research Base, 2013 4 Health Economics Research Group, RAND Europe and Office of Health Economics, Medical Research: What’s it Worth? Estimating the economic benefits from to deliver world-leading science without resource medical research in the UK, 2008 budget for the work that is already being carried out 5 BIS provides block funding to HEIs in England only (through HEFCE). Similar block funding is awarded to the devolved nations through funding councils in Scotland, by talented researchers across the UK. Wales and Northern Ireland 6 Campaign for Science and Engineering (CaSE), Budget Briefing, March 2015 7 Association of Medical Research Charities, www.amrc.org.uk/aboutus 8 “Working together for patients and economic growth” Infographic, Association of Medical Research Charities, 2015 9 Building a stronger future: Research Innovation and Growth, UK National Academies 2015 4 Investing together, changing lives – keeping the UK at the heart of medical research Working together for UK research – the role of Government and charity investment 5 A CAREER IN ReseaRCH THE ROLE OF DIFFERENT FUNDERS IN THE WORK OF OUR BHF Professors DaviD NEWBY Professor David Newby, University of Edinburgh, has been a BHF Professor since 2009. Joint funding from the UK His research focuses on how blood vessels and the heart react in health and disease, Government and the charity sector particularly in heart attacks and heart failure.
Recommended publications
  • CLARIFY Executive Committee
    CLARIFY Executive Committee Philippe Gabriel STEG – Chairman of the Executive Committee Director, Coronary Care Unit, Cardiology Department, Hopital Bichat-Claude Bernard, Paris Professor of Cardiology, Université Paris 7 Denis Diderot, Paris Head of the Research Team “Clinical Research in Atherothrombosis”, INSERM U-698, Paris France Professor Steg has been a Professor of Cardiology in Université Paris 7 - Denis Diderot, since 1994. He works as interventional cardiologist and is director of the Coronary Care Unit of Hôpital Bichat-Claude Bernard in Paris, France. He is also director of the research team “Clinical Research in Atherothrombosis”, in INSERM U-698, Paris. Professor Steg’s research interests are in the field of coronary artery disease. He is involved in studies of mechanical and pharmacologic intervention in acute coronary syndromes, but has also recently turned his attention to secondary prevention, long-term risk assessment and management of atherothrombosis. He is a former president of the Thrombosis Working Group of the French Society of Cardiology and belongs to the nucleus of the Thrombosis Working Group of the European Society of Cardiology. He is a member of the Institut Universitaire de France, a fellow of the European Society of Cardiology, American College of Cardiology, and a American College of Chest Physicians and a co-chair of the subcommittee for Research of the European Relations committee of the European Society of Cardiology. He is currently scientific secretary of the French Society of Cardiology. Professor Steg participated in the steering or executive committees of trials or registries such as CHARISMA, OASIS-5, 6 and 7, PLATO, BEAUTIFUL and STABILITY and is leading several investigator-driven or industry-sponsored clinical trials and registries such as REACH, RUBY-1, OASIS 8/FUTURA, EURIKA, VIVIFY and REALIZE-AF.
    [Show full text]
  • Putting Theory Into Practice in Scotland Annual Report 2017 SCIENCE NOT FICTION
    Putting theory into practice in Scotland Annual Report 2017 SCIENCE NOT FICTION. Message from our Message from Chief Executive Director of BHF Scotland In Scotland we are currently funding over the generosity of supporters It’s been another impressive year Scotland’s Out of Hospital who may be vulnerable. Cardiac Arrest strategy, which £70m of cardiovascular research to help for BHF Scotland, and I’d like to start aims to save lives by equipping identify life saving scientific discoveries Despite these challenges, I am by thanking everyone who’s made 500,000 people with CPR skills which will change people’s lives in the delighted that we remain one it possible. by 2020. future. We’ve also trained 215,000 people of the most loved and trusted charities in the UK. And we’ve built on BHF- in life saving CPR since the launch of our Our recent relocation to funded research showing nation of life savers programme. Looking forward, there are central Edinburgh has ensured the relationship between poor opportunities for us to capitalise we are closer to Government air quality and cardiovascular upon our reputation as a world and healthcare leaders. I’m health. We’re working with These are the headlines of the leader in cardiovascular research extremely proud that we’re the Government and MSPs transformational work of BHF to extend our reach further, and Scotland’s largest independent across parties to build the case Scotland, working on behalf of to use our expertise to influence funder of cardiovascular for tackling poor air quality. the 670,000 people with heart decision makers on how best research, with over £70m We can only do this work thanks and circulatory disease.
    [Show full text]
  • Britain's Biggest Charities
    BRITAIN’S BIGGEST CHARITIES: KEY FEATURES Key findings When we looked at charities with an income over We also looked at the ten super-major charities that £100m, ‘super-major’ charities, between 2009/10 and have experienced the largest income growth. We 2015/16, we found that: found: . Many of the most well-known and long-established . Income from government and investments has charities are super-major, working predominantly in played a key role in their rising income. social services, international development and . The majority of these charities have an international health. focus, and income from the EU, foreign . Super-major organisations are small in number, but governments and international agencies has grew from 26 to 45. Their income and share of the contributed to rising incomes. voluntary sector’s total income has also grown. Income from individuals has not been a factor in . Similar to other charities, super-major charities explaining growth in most cases. receive the largest proportion of their income from individuals. But they receive more of their income from the voluntary sector and less from government. Super-major charities receive a greater proportion of their income from voluntary sources, and less from earned sources, than other charities. Super-major charities spend a similar proportion to other charities on charitable activities, but a greater proportion of this happens through grant making. They account for a nearly a third of the sector’s grant making. Super-major charities hold a significant proportion of the sector’s assets, with much of this held by the Wellcome Trust. Research Briefing | Nov 2018 Britain’s biggest charities: key features 2 Introduction Our approach Every year, NCVO produces the Civil Society We have used the most recent data available from the Almanac, which provides an overview of the voluntary UK Civil Society Almanac 2018, based on the charities’ sector in terms of its size and scope, financial health, annual accounts for the financial year 2015/16.
    [Show full text]
  • Centre for Cardiovascular Science
    2018 Centre for Cardiovascular Science STAFF PROFILES The Centre for Cardiovascular Science is a world-leading centre of excellence that integrates discovery, translational and clinical cardiovascular research to transform the diagnosis, treatment and management of people with heart and circulatory diseases. We are working with local, national and international partners and funders to develop solutions to our research challenges with regional and global impact. Our major research challenges are: 1. To understand the body’s responses to vascular, renal and myocardial injury and to harness mechanisms that can improve tissue repair, remodelling and regeneration. 2. To identify shared mechanisms and novel therapeutic targets for hypertension, vascular dysfunction, small vessel disease, stroke & dementia. 3. To identify therapeutically targetable metabolic drivers of cardiovascular disease across the life course in order to prevent disease progression. 4. To develop novel imaging approaches that will accelerate the mechanistic evaluation of cardiovascular injury and repair, and to use such innovation to guide clinical diagnosis and treatment decisions in patients. 5. To improve diagnosis, risk stratification, and targeting of treatments in patients with heart and circulatory diseases globally, notably by harnessing Scotland’s comprehensive whole population-linked health care data. Cardiovascular Injury, Repair & Regeneration Prof Andy Baker BHF Professor of Translational Cardiovascular Sciences, Gustav Born Chair of Vascular Biology, Head of Centre for Cardiovascular Science Biography Andrew graduated from the University of London in 1990 in pharmacology and toxicology and from the University of Wales College Of Medicine in 1994. His post- doctoral work in Cardiff focused on the development of adenoviral vectors for gene delivery studies in the cardiovascular system.
    [Show full text]
  • Mitral Valve Disease–Morphology and Mechanisms Robert A
    Mitral valve disease–morphology and mechanisms Robert A. Levine, Albert A. Hagége, Daniel P. Judge, Muralidhar Padala, Jacob P. Dal-Bianco, Elena Aikawa, Jonathan Beaudoin, Joyce Bischoff, Nabila Bouatia-Naji, Patrick Bruneval, et al. To cite this version: Robert A. Levine, Albert A. Hagége, Daniel P. Judge, Muralidhar Padala, Jacob P. Dal-Bianco, et al.. Mitral valve disease–morphology and mechanisms. Nature Reviews Cardiology, Nature Publishing Group, 2015, 12 (12), pp.689–710. 10.1038/nrcardio.2015.161. hal-01830969 HAL Id: hal-01830969 https://hal.archives-ouvertes.fr/hal-01830969 Submitted on 13 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. HHS Public Access Author manuscript Author Manuscript Author ManuscriptNat Rev Author ManuscriptCardiol. Author Author Manuscript manuscript; available in PMC 2016 March 23. Published in final edited form as: Nat Rev Cardiol. 2015 December ; 12(12): 689–710. doi:10.1038/nrcardio.2015.161. Mitral valve disease—morphology and mechanisms Robert A. Levine*, Albert A. Hagége*, Daniel P. Judge*, Muralidhar Padala‡, Jacob P. Dal- Bianco‡, Elena Aikawa, Jonathan Beaudoin, Joyce Bischoff, Nabila Bouatia-Naji, Patrick Bruneval, Jonathan T. Butcher, Alain Carpentier, Miguel Chaput, Adrian H.
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptNat Genet Author Manuscript. Author manuscript; Author Manuscript available in PMC 2016 April 01. Published in final edited form as: Nat Genet. 2015 October ; 47(10): 1206–1211. doi:10.1038/ng.3383. Genetic association analyses highlight biological pathways underlying mitral valve prolapse Christian Dina1,2,33, Nabila Bouatia-Naji3,4,33, Nathan Tucker5,33, Francesca N. Delling6,7, Katelynn Toomer8, Ronen Durst9, Maelle Perrocheau3,4, Leticia Fernandez-Friera10,11, Jorge Solis10,11, PROMESA investigators12, Thierry Le Tourneau1,2, Ming-Huei Chen7,13, Vincent Probst1,2, Yohan Bosse14, Philippe Pibarot14, Diana Zelenika15, Mark Lathrop15,16, Serge Hercberg4,17,18,19,20, Ronan Roussel20,21,22, Emelia J. Benjamin6,7, Fabrice Bonnet23,24, LO Su Hao25, Elena Dolmatova5, Floriane Simonet1, Simon Lecointe1,2, Florence Kyndt1,2, Richard Redon1,2, Hervé Le Marec1,2, Philippe Froguel26,27, Patrick T. Ellinor5,28, Ramachandran S. Vasan6, Patrick Bruneval3,4,29, Russell A. Norris8,35, David J. Milan5,35, Susan A. Slaugenhaupt30,35, Robert A. Levine31,35, Jean-Jacques Schott1,2,35, Albert A. Hagege3,32,35, MVP-France12, Xavier Jeunemaitre3,4,33,35, and Leducq Transatlantic MITRAL Network11 1Inserm UMR1087, CNRS UMR 6291, Institut du Thorax, Nantes, France 2Centre Hospitalier Universitaire (CHU) Nantes, Université de Nantes, France 3Inserm UMR970 Paris Cardiovascular Research Center, Paris, France 4Paris Descartes University, Paris Sorbonne Cité, Paris, France 5Cardiovascular Research Center, Massachusetts General Hospital, Charlestown MA, USA 6Framingham Heart Study, Framingham, MA, USA Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms Correspondence should be addressed to: CD ([email protected]), N.B-N ([email protected]) or X.J ([email protected]).
    [Show full text]
  • Dietary Spermidine for Lowering High Blood Pressure
    CORE Metadata, citation and similar papers at core.ac.uk Provided by RERO DOC Digital Library AUTOPHAGY 2017, VOL. 13, NO. 4, 1–3 http://dx.doi.org/10.1080/15548627.2017.1280225 AUTOPHAGIC PUNCTA Dietary spermidine for lowering high blood pressure Tobias Eisenberga,b,y, Mahmoud Abdellatifc,y, Andreas Zimmermanna, Sabrina Schroedera, Tobias Pendla, Alexandra Hargera,d, Slaven Stekovica, Julia Schipkee,f, Christoph Magnesg,AlbrechtSchmidtc, Christoph Ruckenstuhla, Christopher Dammbruecka,AngelinaS.Grossa,ViktoriaHerbstc, Didac Carmona-Gutierreza, Federico Pietrocolah,i,j,k,l, Thomas R. Pieberb,d,g, Stephan J. Sigristm,n,WolfgangA.Linkeo, Christian Muhlfeld€ e,f,JunichiSadoshimap, Joern Dengjelq,r, Stefan Kiechls, Guido Kroemerh,i,j,k,l,t,u, Simon Sedejb,c, and Frank Madeoa,b aInstitute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria; bBioTechMed Graz, Graz, Austria; cDepartment of Cardiology, Medical University of Graz, Graz, Austria; dDepartment of Internal Medicine, Medical University of Graz, Graz, Austria; eInstitute of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany; fCluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy), Hannover, Germany; gJoanneum Research Forschungsgesellschaft m.b.H., HEALTH, Institute for Biomedicine and Health Sciences, Graz, Austria; hEquipe 11 Labellisee Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; iCell Biology and Metabolomics Platforms, Gustave Roussy Comprehensive Cancer Center, Villejuif, France;
    [Show full text]
  • Download the Feasibility Report
    CVDPREVENT A National Primary Care Audit FEASIBILITY REPORT The CVDPREVENT feasibility project has been led and funded by the British Heart Foundation. Prepared by PRIMIS June 2018 © The University of Nottingham. All rights reserved. CVDPREVENT Feasibility Report Amendment History: Version Date Amendment History Changes made v0.1 05/04/18 First draft N/A v0.2 02/05/18 Review of document Changes to sections 1 and 6 v6.9 05/06/18 Review of document References added Clinical indicators added as Appendix 1 Initial scope document added as Appendix 7 v7.0 07/06/2018 Final draft for approval v7.2 18/07/2018 Minor Addition of BHF logo Forecast changes: Anticipated change When Annual review May 2019 Approvals: This document must be approved by the following: Group/Individual Date sent Return date Version V2.0 Document status: This is a controlled document. A paper copy of this document is uncontrolled and it is up to the reader to ensure that it is the latest copy by checking on the network. CVDPREVENT Feasibility Report_Final_v7.0 Page 2 28th June 2018 CVDPREVENT Feasibility Report TABLE OF CONTENTS 1. Strategic overview .......................................................................................... 4 2. Introduction .................................................................................................... 6 3. Background .................................................................................................... 6 4. The GP IT system landscape ........................................................................
    [Show full text]
  • Keeping Pace Progress in Dementia Research Capacity March 2017 Contents
    Keeping pace Progress in dementia research capacity March 2017 Contents Executive Summary 3 Recommendations 4 1. Introduction 5 2. Methodology 6 3. Progress 7 3.1 Research output 7 3.2 Estimate of number of dementia researchers 10 3.3 Research outputs and capacity in comparison with disease costs 13 3.4 Dementia research collaboration 15 4. Discussion 21 4.1 Good progress, but we can’t be complacent 21 4.2 Policy challenges 23 5. Review of progress since 2012 25 6. Conclusions and next steps 27 6.1 Areas where further action is required 27 6.2 Recommendations 28 7. References 29 2 Executive Summary As the UK’s leading dementia research charity, we see the importance in keeping our finger on the pulse of what’s happening in dementia research. In 2012, our Defeating Dementia report used bibliometric analysis to assess research productivity and capacity in the UK and other countries, revealing a sharp disparity between provision for research into dementia compared to other major diseases. The past five years have seen a backdrop of increased political support and financial investment for dementia research, but what difference has that made to the research landscape? To answer this question, we repeated this analysis to assess the progress made since our initial Defeating Dementia 2012 report was published. Between 2008-9 and 2014-15 The number of UK The number of UK dementia publications dementia researchers has almost has almost doubled doubled 3,209 1,614 to to 3,169 6,141 The ratio of UK dementia researchers to cancer researchers is now For every 1 to 4 £2 million of disease costs, in 2014-15 there was: Dementia researcher Cancer researchers Internationally collaborative UK dementia publications have Coronary heart disease researchers increased from 51% to 61% 1 dementia researcher compared to 10 for cancer, 5 for coronary heart disease and 4 for stroke.
    [Show full text]
  • CVD-COVID-UK Consortium Members (15Th June 2021)
    CVD-COVID-UK Consortium Members (15th June 2021) Institution Member Name Institution Member Name Institution Member Name Addenbrooke's Hospital Jon Boyle King's College London Charles Wolfe Swansea University Jane Lyons British Heart Foundation Dan O’Connell King's College London Elena Nikiphorou Swansea University Julian Halcox British Heart Foundation Kate Cheema King's College London Harry Watson Swansea University Laura North British Heart Foundation Millie Ellis King's College London Irene Higginson Swansea University Elizabeth A Ellins British Heart Foundation Naomi Herz King's College London Katherine Sleeman Swansea University Ronan Lyons British Heart Foundation Nilesh Samani King's College London Mevhibe Hocaoglu Swansea University Rowena Griffiths British Heart Foundation Sonya Babu-Narayan King's College London Rachel Cripps The Alan Turing Institute Sebastian Vollmer Cancer Research UK Jon Shelton London School of Hygiene & Tropical Medicine Qiuju Li University College London Alex Handy Cancer Research UK Lars Murdock Newcastle University Mike Simpson University College London Alvina Lai Cancer Research UK Martina Slapkova NHS Digital Brian Roberts University College London Ami Banerjee Cancer Research UK Rebecca Crallan NHS Digital Russell Healey University College London Ashkan Dashtban Cancer Research UK Rosie Hinchliffe NHS Digital Sam Hollings University College London Caroline Dale Cancer Research UK Shane Johnson NHS Digital Steve Ball University College London Christopher Tomlinson European Bioinformatics Institute
    [Show full text]
  • Research Spend in the UK: Comparing Stroke, Cancer, Coronary Heart
    Research Spend in the UK Comparing stroke, cancer, coronary heart disease and dementia A report produced by the Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford for the Stroke Association Ramon Luengo-Fernandez, Jose Leal, Alastair Gray FULL REPORT Acknowledgements We are grateful to the Charity Commission for providing us with a comprehensive list of relevant charities. The help received from the Chief Scientist Office, Scottish Government Health and Social Care Directorates, who provided us with a comprehensive list of research grants they funded, is also gratefully acknowledged. Finally our thanks go to Archie Gray for his assistance in collating data for this report. Contents Acknowledgements 2 Contents 3 Foreword by Jon Barrick 4 Foreword by Professor Tony Rudd CBE 5 Key Findings 6 Executive Summary 8 Section 1 12 Introduction Objectives Section 2 14 Methods: Research Funding Governmental Health Research Funding Charity Health Funding Section 3 18 Methods: Disease Burden Disease Prevalence Disability Adjusted Life Years (DALYs) Economic Burden Section 4 20 Results: Research Funding Sample Governmental Organisations Charities Levels Of Research Funding Research Funding And Burden of Disease Section 5 24 Discussion References 28 Appendix 1 Research Funding By Government: 30 Included Research Grant Programmes Appendix 2 Research Funding By Government: 32 Included Research Infrastructure Programmes Appendix 3 List Of Included Charities 34 Stroke Association 3 Foreword Stroke is the biggest cause of complex disability worldwide, with an estimated 1.2 million stroke survivors in the UK today. Living with the long term impact of the condition can be devastating, yet research funding dedicated to stroke remains disproportionately small.
    [Show full text]
  • Lipoprotein(A) and Cardiovascular Risk Prediction Among Women
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Am Coll Manuscript Author Cardiol. Author Manuscript Author manuscript; available in PMC 2019 July 17. Published in final edited form as: J Am Coll Cardiol. 2018 July 17; 72(3): 287–296. doi:10.1016/j.jacc.2018.04.060. Lipoprotein(a) and Cardiovascular Risk Prediction among Women Nancy R. Cook, ScD, Samia Mora, MD, and Paul M Ridker, MD Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA Abstract Background—While lipoprotein(a) [Lp(a)] is associated with incident cardiovascular disease (CVD), its contribution to prediction remains controversial. Objective—We examined the association and clinical utility of Lp(a) with incident CVD in women. Methods—A turbidimetric assay assessed Lp(a) in three cohorts of women [the Women’s Health Study (WHS, N=24,558), a case-cohort sample from the Women’s Health Initiative Observational Study (WHI, 1815 cases, subcohort =1989), and the Justification for Use of Statins in Prevention (JUPITER) trial (N=2,569)] and men from JUPITER (N=5,161). A WHS derivation sample (N=16,400) determined the form of association with incident CVD. This was tested in WHS validation data (N=8,158) and the other study samples. Models including traditional CV risk factors but with and without Lp(a) were compared using risk reclassification. Results—In the WHS there was a curvilinear association, with increased CVD risk among those with Lp(a) above 50 mg/dL, but only among women with total cholesterol (TC) above 220 mg/dL.
    [Show full text]